Pixel CO2 (FemiLift) laser treatment for vulvo-vaginal atrophy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center interventional trial at Hillel Yaffe Medical Center enrolls postmenopausal women aged 45–75 with symptomatic vulvo-vaginal atrophy and no active vaginal infection. Participants receive treatments with the Pixel fractional CO2 (FemiLift) laser and are followed for clinical symptom changes and safety. The study includes molecular and histologic assessments of vaginal tissue such as epithelial thickness, collagen content, glycogen levels, fibroblast density, and vascularity to document tissue regeneration. Standard screening (PAP, urine testing) and gynecological exams are used to confirm eligibility and monitor adverse events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Female 45-75 years of age, at the time of enrolment.
2. Provided written informed consent.
3. Spontaneous induced menopause as defined by one of the followings:

   * Amenorrhea of ≥12 months
   * After bilateral oophorectomy
   * FSH levels\>30 IU
4. One or more VVA related symptoms (i.e., itching, dryness, burning, pain, dyspareunia, or dysuria), after other possible causes of these complaints have been excluded.
5. Characteristic atrophic changes (see above) on gynaecological examination.
6. Normal Papanicolaou (PAP) smear test from the last 3-5 years: if needed and as indicated according to the Israeli guidelines.
7. Negative urine analysis test - urine stick.
8. Asymptomatic for bacterial or fungal vaginitis.
9. Vaginal canal, introitus and vestibule free of injuries and bleeding.
10. Able and willing to comply with the treatment/ follow-up schedule and requirements.
11. Normal general gynecological exam from the last year including US.

Exclusion Criteria:

1. Vaginal Health Index Score (VHIS) \< 5.
2. Active genital infection.
3. Vaginal bleeding which did not underwent evaluation.
4. Previous vulvar, vaginal or cervical dysplasia, within the last 2 years, or previous cancer.
5. Recurring urinary tract infection or recurring infection of genital herpes (≥ 3 episodes in the recent year).
6. Pelvic Organ prolapse (POP) \>II, according to the pelvic organ prolapse quantification system (POP-Q).
7. Serious systemic disease or any chronic condition that could interfere with study compliance.
8. Any local, systemic and/or chronic autoimmune infection.
9. Taken part in a clinical trial concerning VVA, within 30 days prior to the enrolment.
10. Allergy to lidocaine or tetracaine.
11. Genital skin disease that may interfere with the treatment (these subjects should be included/excluded according to the investigator's discretion).
12. Use of anticoagulants, within 5 days prior to enrolment.
13. Active positive HPV test.
14. Active positive HSV (Acute or actively present within the last 2 months).
15. Heavy smoker (\>1 pack of cigarettes a day)
16. Any disease or medication that may interfere with the wound healing/immune function.
17. Pregnancy / breast feeding.
18. Any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromise the subject safety.

Where it's running

• Hille Yaffe Medical Center
  Hadera, Israel Recruiting

Study contacts

• Principal investigator: Jonia Alsheik, MD — Hillel Yaffe Medical Center
• Study coordinator: Jonia Alsheik, MD
• Email: osnatp@hymc.gov.il
• Phone: +972-4-7744602

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• F-GYN injection for vaginal dryness and vaginal/vestibular atrophy

  This study tests whether a one-time F-GYN injection can relieve vaginal dryness and related symptoms in adult women with atrophic vaginitis/vestibulovaginal atrophy compared with standard non-hormonal care.

  Recruiting at 3 sites Biovico Sp. z o.o. · Bolesławice and 2 other locations · NCT07701863

• Nonhormonal vulvovaginal gel to relieve menopausal vulvovaginal symptoms

  This will test a hormone-free vulvovaginal gel in postmenopausal women with genitourinary syndrome of menopause to see if it reduces vaginal atrophy symptoms and improves daily quality of life.

  Recruiting Mucosa Innovations, S.L. · Madrid, Madrid · NCT06962345

• Treatment for vaginal atrophy and related conditions using a novel gel dressing

  This study is testing a new gel dressing to see if it can help adult women with vaginal atrophy and other skin conditions feel better.

  Recruiting at 6 sites Stratpharma AG · Birmingham, Alabama and 13 other locations · NCT05953090

• Observing vulvar diseases in Nigeria

  This study looks at how much people in Nigeria know about vulvar diseases and how common these conditions really are in different communities.

  Recruiting KDRS ltd · London · NCT05890092

• Using vaginal estrogen to improve sexual function in breastfeeding patients after childbirth

  This study tests if using vaginal estrogen cream can help breastfeeding women improve their sexual function after giving birth.

  Recruiting Phase 4 University Hospitals Cleveland Medical Center · Cleveland, Ohio · NCT05457972

• Vaginal CO2 laser for vaginal dryness in breast cancer survivors

  This trial will test whether a vaginal fractional CO2 laser can reduce vaginal dryness in women who have finished breast cancer treatment.

  Recruiting at 2 sites Phase 3 Alliance for Clinical Trials in Oncology · Des Moines, Iowa and 2 other locations · NCT05379153

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.